GlassScriptPhysician profile
Bryant C Sheh
NPI 1801092242
$808.07
in general payments reported to CMS, 2019-2025
20 companies · $509 in 2025
The $509 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.37 · 2021: $13.93 · 2022: $95.57 · 2023: $29.36 · 2024: $147 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673 · Education: $12.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.78 |
| Education | $12.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $133.53 | 2022-2025 | |
| Janssen Biotech, INC. | $107.31 | 2024-2025 | Rybrevant, Erleada, Akeega |
| Acrotech Biopharma INC. | $77.70 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $62.81 | 2020-2025 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $45.86 | 2025 | Enhertu |
| Tempus Ai, INC | $36.99 | 2025 | Xt Cdx |
| Deciphera Pharmaceuticals INC. | $33.01 | 2025 | Qinlock, Romvimza |
| Novartis Pharmaceuticals Corporation | $29.36 | 2023 | |
| Daiichi Sankyo INC. | $28.29 | 2025 | Enhertu |
| Celgene Corporation | $27.91 | 2025 | |
| Agios Pharmaceuticals, INC. | $27.80 | 2025 | Pyrukynd |
| Takeda Pharmaceuticals U.S.A., INC. | $27.63 | 2025 | Iclusig |
| Adaptive Biotechnologies Corporation | $27.57 | 2024 | Clonoseq |
| Genzyme Corporation | $26.53 | 2025 | |
| Lilly USA, LLC | $22.13 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $21.83 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| E.R. Squibb & Sons, L.L.C. | $21.37 | 2024 | Opdivo |
| Array Biopharma INC | $20.15 | 2024 | Braftovi, Lorbrena, Xalkori |
| Glaxosmithkline, LLC. | $17.87 | 2025 | Ojjaara |
| Gilead Sciences, INC. | $12.42 | 2025 | Trodelvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryant Sheh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.